Autoimmune Monoclonal Antibody Industry Valued at $98.81 Billion by 2029 With CAGR of 8.4% | Size and Share Insights
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#What Is the Forecast for the Autoimmune Monoclonal Antibody Market from 2024 to 2025?#_x000D_
In the past few years, the market size of monoclonal antibodies for autoimmune diseases has experienced robust growth. The market is projected to increase from $65.83 billion in 2024 to $71.71 billion in 2025, with a compound annual growth rate (CAGR) of 8.7%. Factors contributing to the growth during the historic period include a rise in autoimmune diseases, greater adoption of biologics for treatment, increased knowledge about targeted therapies, expedited approvals for monoclonal antibody drugs, and expanded healthcare access in developed nations._x000D_
_x000D_
#What Is the Projected Market Size of the Autoimmune Monoclonal Antibody Market?#_x000D_
A robust increase in the autoimmune monoclonal antibody market is anticipated in the forthcoming years, with expectations to reach $98.81 billion by 2029 at a compound annual growth rate (CAGR) of 8.4%. Factors contributing to the growth during this period include the burgeoning demand for individualized medicine, the rising uptake of biosimilars, an increase in clinical trials related to autoimmune therapy, a growing aging population, and an escalation in the occurrence of chronic immune disorders. Noteworthy trends in the predicted period involve advancements in antibody engineering, the creation of bispecific antibodies, the amplified utilization of artificial intelligence in drug discovery, the incorporation of genomics in devising treatment plans, and innovative drug delivery systems._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=24162&type=smp_x000D_
_x000D_
#Who are the Major Competitors in the Autoimmune Monoclonal Antibody Market Outlook?#_x000D_
Major companies operating in the autoimmune monoclonal antibody market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., UCB S.A., Genmab A/S, Zymeworks Inc., Xencor Inc., Immutep Limited, Cue Biopharma Inc., Santa Ana Bio Inc._x000D_
_x000D_
#What Is Fueling Growth in the Autoimmune Monoclonal Antibody Market?#_x000D_
The surge in the need for biologics is anticipated to accelerate the expansion of the autoimmune monoclonal antibody market in future. Biologics constitute a class of medical goods obtained from living beings or their elements, applied in treating, preventing, or diagnosing ailments. The rising need for biologics is primarily propelled by their capacity to effectively manage intricate illnesses such as cancer, autoimmune disorders, and genetic conditions, where conventional therapies may not be as beneficial. Biologic therapies are enhanced by autoimmune monoclonal antibodies which provide targeted immune modulation, making them ideal for controlling hyperactive immune reactions. They lessen the reliance on general immunosuppressants by establishing accurate treatments, enhancing patient results and reducing side effects. For instance, in June 2024, Cardinal Health Inc., a US-based healthcare company, reported that out of the 40 Food and Drug Administration (FDA) approved biosimilar products in 2023, 25 are readily accessible in the US market, marking an increase from the 33 biosimilar products in 2022. Consequently, the escalating demand for biologics is fuelling the development of the autoimmune monoclonal antibody market._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=24162&type=smp_x000D_
_x000D_
#Which Autoimmune Monoclonal Antibody Market Segments Are Growing the Fastest?#_x000D_
The autoimmune monoclonal antibody market covered in this report is segmented –_x000D_
_x000D_
1) By Type: Immunoglobulin G Monoclonal Antibodies, Immunoglobulin M Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Fully Human Monoclonal Antibodies_x000D_
2) By Route Of Administration: Subcutaneous, Intravenous, Intramuscular_x000D_
3) By Application: Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus, Psoriasis, Inflammatory Bowel Disease_x000D_
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy_x000D_
5) By End User: Hospitals, Outpatient Clinics, Homecare Settings, Research Institutions_x000D_
_x000D_
Subsegments:_x000D_
1) By Immunoglobulin G (IgG) Monoclonal Antibodies: Immunoglobulin G1 (IgG1), Immunoglobulin G2 (IgG2), Immunoglobulin G3 (IgG3), Immunoglobulin G4 (IgG4)_x000D_
2) By Immunoglobulin M (IgM) Monoclonal Antibodies: Pentameric Immunoglobulin M (IgM), Hexameric Immunoglobulin M (IgM)_x000D_
3) By Chimeric Monoclonal Antibodies: Murine Variable Region + Human Constant Region, Humanized Variable Region + Murine Constant Region_x000D_
4) By Fully Human Monoclonal Antibodies: Phage Display-Derived, Transgenic Mouse-Derived, Fully Human Hybridoma-Derived_x000D_
_x000D_
#Which Industry Trends Are Shaping the Future of the Autoimmune Monoclonal Antibody Market?#_x000D_
Leading businesses in the autoimmune monoclonal antibody market are concentrating on creating novel solutions like biosimilar development to improve safety, efficacy, and quality. This development of biosimilars refers to the process of creating biological products that are highly similar, safe, and effective, comparable to already approved biologics. This involves the use of sophisticated biotechnology, stringent analytical testing, and clinical studies that showcase comparable efficiency, safety and quality, all for regulatory approval. For example, in February 2025, Biocon Biologics Limited, a biopharmaceutical entity based in India, released YESINTEK, a biosimilar developed to cope with autoimmune disorders such as Crohn’s disease, ulcerative colitis, and psoriasis. This product works by targeting and limiting the functioning of interleukin-12 and interleukin-23, thus reducing inflammation and controlling the immune response. By imitating the reference product stelara, Yesintek aids in managing these conditions in the long run while making biologic therapies more accessible to patients._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#Which Countries Are Leading the Autoimmune Monoclonal Antibody Market?#_x000D_
North America was the largest region in the autoimmune monoclonal antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autoimmune monoclonal antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=24162&type=smp_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the autoimmune monoclonal antibody market, and how is it changing globally?_x000D_
2. Who are the major companies in the autoimmune monoclonal antibody market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the autoimmune monoclonal antibody market right now?_x000D_
4. Which products or customer segments are growing the most in the autoimmune monoclonal antibody market?_x000D_
5. What factors are helping or slowing down the growth of the autoimmune monoclonal antibody market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Europe +44 7882 955267_x000D_
Asia & Others +44 7882 955267 & +91 8897263534_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
